Silexion Therapeutics Corp (SLXN) stock
SLXNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SLXNW
$1.44−0.21 (-12.73%)
Close on Nov 18, 2026Market cap $868.40KP/E –Yield –
Silexion Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Silexion Therapeutics's operating income for the twelve months ending Sep 30, 2026 was -$13.52M. For fiscal 2025 it was -$11.63M.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$11.63M | – |
| FY2024 | Dec 31, 2024 | -$12.57M | – |
| FY2023 | Dec 31, 2023 | -$4.68M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$2.68M | – |
| Q2 FY2026 | Jun 30, 2026 | -$3.68M | – |
| Q1 FY2026 | Mar 31, 2026 | -$2.75M | – |
| Q4 FY2025 | Dec 31, 2025 | -$4.41M | – |
| Q3 FY2025 | Sep 30, 2025 | -$3.29M | – |
| Q2 FY2025 | Jun 30, 2025 | -$2.28M | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.65M | – |
| Q4 FY2024 | Dec 31, 2024 | -$1.90M | – |
| Q3 FY2024 | Sep 30, 2024 | -$8.04M | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.39M | – |
| Q1 FY2024 | Mar 31, 2024 | -$1.25M | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.73M | – |
| Q3 FY2023 | Sep 30, 2023 | -$731.00K | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.41M | – |
See a number that looks wrong?